(Q38843774)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Celia Morgan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Valerie Curran

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

David Nutt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Anne Schlag

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Rupert McShane

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

5 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

published in

The Lancet Psychiatry

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

419-426

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3β.

17 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine use: a review

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine--the real perspective

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Antidepressant effects of ketamine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine and other glutamate receptor modulators for depression in adults

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine-associated ulcerative cystitis: a new clinical entity.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine-associated lower urinary tract destruction: a new radiological challenge

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Long-term ketamine abuse induces cystitis in rats by impairing the bladder epithelial barrier

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Urinary tract disease associated with chronic ketamine use

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

A randomized controlled trial of intranasal ketamine in major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Role of ketamine in acute postoperative pain management: a narrative review

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Effects of ketamine in normal and schizophrenic volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Psychiatric safety of ketamine in psychopharmacology research

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Use of Ketamine in Clinical Practice: A Time for Optimism and Caution

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Antidepressant treatment response: 'I want it all, and I want it now!'†.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Proceed with caution: off-label ketamine treatment for major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Research Moratoria and Off-Label Use of Ketamine.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

An Ethical Exploration of Barriers to Research on Controlled Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

A word to the wise about ketamine

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

To use or not to use: an update on licit and illicit ketamine use

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Is ketamine ready to be used clinically for the treatment of depression?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

The public stigma of mental illness: what do we think; what do we know; what can we prove?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Treatment-resistant depression: therapeutic trends, challenges, and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Risk factors for suicide in individuals with depression: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Off-label drug use in psychiatry: A retrospective audit in a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006-2015.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Are RCTs the Gold Standard?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

A philosopher's view of the long road from RCTs to effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Personalized medicine: Time for one-person trials

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ethics needs principles--four can encompass the rest--and respect for autonomy should be "first among equals"

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Empty ethics: the problem with informed consent

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Some limits of informed consent

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Cognition and depression: current status and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Paternalism, autonomy and reciprocity: ethical perspectives in encounters with patients in psychiatric in-patient care

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ethical issues in deep brain stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Ketamine for chronic pain: risks and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Oral ketamine for the treatment of pain and treatment-resistant depression†.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Research on Controlled Drug Use: A Paradigm for Public Health Research in Sustainable Health

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Risk management of drug products and the U.S. Food and Drug Administration: evolution and context

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

Case histories in pharmaceutical risk management

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2817%2930102-5

7 January 2021

10.1016/S2215-0366(17)30102-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28395988%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference